RESEARCH TRIANGLE PARK — BioCryst Pharmaceuticals has licensed commercialization rights in Japan to Torii Pharmaceutical for BCX7353, an oral, once-daily treatment for the prevention of hereditary angioedema (HAE) attacks.
The RTP-based biotech company focused on rare disease development will receive a $22 million upfront payment. It is eligible to receive up to an additional $20 million upon achievement of certain milestones, it said in its release today.
In addition, BioCryst will receive tiered royalties ranging from the mid-teens to potentially 40 percent of Japanese net sales of BCX7353.
“We are excited to partner with Torii to accelerate access for Japanese patients to BCX7353,” said Jon Stonehouse, president and chief executive officer of BioCryst, in a statement.
“Torii has a strong and recent history of significant commercial success as a Japanese partner, and the breadth of experience and infrastructure to build the prophylactic HAE market with BCX7353.”
BioCryst said it has received Orphan Drug and Sakigake designation for BCX7353 and plans to submit a Japanese New Drug application (JNDA) to the Pharmaceuticals and Medical Devices Agency (PMDA) in the first quarter of 2020.
“Given its clinical profile and the tremendous unmet need of HAE patients here in Japan, we are honored to add BCX7353 to our portfolio,” said Goichi Matsuda, president of Torii.
“We are well positioned to use our experience in building disease awareness, in driving patient identification, and our broad reach across the base of treaters, including dermatologists, allergists, and other specialists, to bring this important treatment to HAE patients.”